Top

01-02-2018 | Bladder cancer | Article

Assessment of content validity for patient-reported outcome measures used in patients with non-muscle invasive bladder cancer: a systematic review

Journal: Supportive Care in Cancer

Authors: Claudia Rutherford, Manish I. Patel, Margaret-Ann Tait, David P. Smith, Daniel S. J. Costa, Madeleine T. King

Publisher: Springer Berlin Heidelberg

Abstract

Objective

Non-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring ongoing treatment and endoscopic examinations that are frequent and can be life-long. To ensure the comprehensive assessment of the benefits and harms of treatments for NMIBC, the impact on important and relevant patient-reported outcomes (PROs) should be determined. We systematically reviewed the NMIBC PRO literature to determine the suitability of available PRO measures (PROMs) for use in evaluating patient outcomes in NMIBC research.

Methods

We searched six electronic databases, reference lists, and key authors. Two reviewers independently applied inclusion and quality criteria and extracted findings. PROM domains, item content, and content coverage and relevance were determined for identified PROMs. Content validity was assessed against an empirically derived NMIBC-specific conceptual framework that includes 11 PRO domains and 19 sub-domains.

Results

Seventeen studies assessed PROs related to NMIBC and treatment impact. From these studies, 11 PROMs were identified, including three generic, three cancer-specific, and five symptom-specific. None of the PROMs cover all PRO domains important in NMIBC as assessed against our conceptual framework. The EORTC QLQ-C30 plus the NMIBC24 module was best aligned to the conceptual model, but failed to represent six outcomes important to NMIBC patients.

Conclusions

Currently, some outcomes important in NMIBC are inadequately covered by generic and cancer-specific measures despite similar conceptual models. This review identified gaps in the literature regarding assessment of symptoms and other PROs considered important by NMIBC patients. Careful consideration of PROM item content is required when selecting outcome measures for use in future NMIBC clinical trials to ensure that appropriate measures are used to assess outcomes that matter to patients.

Cheluvappa R, Smith DP, Cerimagic S, Patel MI (2014) A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. Int Urol Nephrol 46(7):1351–1360. https://doi.org/10.1007/s11255-014-0643-z CrossRefPubMed

Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics 21(18):1315–1330. https://doi.org/10.1007/BF03262330 CrossRefPubMed

Heney NM (1992) Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin N Am 19(3):429–433

Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M, Jurion F, Palfliet K, Denis O, Simon J, Schulman CC (2000) What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 37(4):470–477CrossRefPubMed

Anastasiadis A, de Reijke TM (2012) Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 4(1):13–32. https://doi.org/10.1177/1756287211431976 CrossRefPubMedPubMedCentral

Australian Institute of Health and Welfare (AIHW) (2014) Cancer in Australia: an overview 2014. http://webarchive.nla.gov.au/gov/20150622042034/http://www.aihw.gov.au/cancer/cancer-in-australia-overview-2014/appendixb/. Accessed 22/06/2015

Aldousari S, Kassouf W (2010) Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J 4(1):56–64CrossRefPubMedPubMedCentral

Hendricksen K, Gleason D, Young JM, Saltzstein D, Gershman A, Lerner S, Witjes JA (2008) Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol 180(1):116–120. https://doi.org/10.1016/j.juro.2008.03.031 CrossRefPubMed

Miyazaki J, Hinotsu S, Ishizuka N, Naito S, Ozono S, Akaza H, Nishiyama H (2013) Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer. Jpn J Clin Oncol 43(8):827–834. https://doi.org/10.1093/jjco/hyt086 CrossRefPubMed

10.

Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15(1):116–123. https://doi.org/10.1200/jco.1997.15.1.116 CrossRefPubMed

11.

Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, O'Neill R, Kennedy DL (2007) Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10(2):S125–S137. https://doi.org/10.1111/j.1524-4733.2007.00275.x CrossRefPubMed

12.

Kamat AM, Sylvester RJ, Bohle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 34(16):1935–1944. https://doi.org/10.1200/jco.2015.64.4070 CrossRefPubMedPubMedCentral

13.

Bottomley A, Flechtner H, Efficace F, Vanvoorden V, Coens C, Therasse P, Velikova G, Blazeby J, Greimel E, EORTC Data Centre and Quality of Life Group (2005) Health related quality of life outcomes in cancer clinical trials. Eur J Cancer 41(12):1697–1709CrossRefPubMed

14.

Snyder C, Aaronson N, Choucair A, Elliot T, Greenhaigh J, Haylyard M, Hess R, Miller D, Reeve B, Santana M (2012) Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res 21(8):1305–1314. https://doi.org/10.1007/s11136-011-0054-x CrossRefPubMed

15.

Metwally MA, Frederiksen KD, Overgaard J (2014) Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol 53(5):654–661. https://doi.org/10.3109/0284186x.2013.864050 CrossRefPubMed

16.

Borras JM, Sanchez-Hernandez A, Navarro M, Martinez M, Mendez E, Ponton JL, Espinas JA, Germa JR (2001) Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. BMJ 322(7290):826. https://doi.org/10.1136/bmj.322.7290.826 CrossRefPubMedPubMedCentral

17.

Rutherford C, Costa DSJ, King MT, Smith DP, Patel MI (2017) A conceptual framework for patient-reported outcomes in non-muscle invasive bladder cancer. Support Care Cancer 25(10):3095–3102. https://doi.org/10.1007/s00520-017-3717-5 CrossRef

18.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269, w264. https://doi.org/10.7326/0003-4819-151-4-200908180-00135 CrossRefPubMed

19.

Messick S (1980) Test validity and ethics of assessment. Am Psychol 35(11):1012–1027. https://doi.org/10.1037/0003-066X.35.11.1012 CrossRef

20.

Blazeby JM, Hall E, Aaronson NK, Lloyd L, Waters R, Kelly JD, Fayers P (2014) Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol 25(14):163–168

21.

Bohle A, Balck F, von Weitersheim J, Jocham D (1996) The quality of life during intravesical bacillus Calmette-Guerin therapy. J Urol 155(4):1221–1226. https://doi.org/10.1016/S0022-5347(01)66224-4 CrossRefPubMed

22.

Colombo R, Bertini R, Salonia A, Da Pozzo LF, Montorsi F, Brausi M, et al. (2001) Nerve and seminal sparing radical cystectomy with orthotopic urinary diversion for select patients with superficial bladder cancer: an innovative surgical approach. J Urol. 165(1):51–5.CrossRefPubMed

23.

Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, Briganti A, Salonia A, Rigatti P, Montorsi F (2012) Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 62(5):797–802. https://doi.org/10.1016/j.eururo.2012.05.032 CrossRefPubMed

24.

Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F (2013) The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol 190(3):857–862. https://doi.org/10.1016/j.juro.2013.03.097 CrossRefPubMed

25.

Hinojosa-Lindsey M. (2011) Understanding treatment-related symptoms, symptom management techniques, and symptom management self-efficacy in a sample of non-muscle invasive bladder cancer patients. Dissertation Abstracts International: Section B: The Sciences and Engineering. 72(1-B):214

26.

Koga H, Ozono S, Tsushima T, Tomita K, Horiguchi Y, Usami M, Hirao Y, Akaza H, Naito S (2010) Maintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol 17(9):759–766. https://doi.org/10.1111/j.1442-2042.2010.02584.x CrossRefPubMed

27.

Kowalkowski MA, Chandrashekar A, Amiel GE, Lerner SP, Wittmann DA, Latini DM, Goltz HH (2014) Examining sexual dysfunction in non-muscle-invasive bladder cancer: results of cross-sectional mixed-methods research. Sex Med 2(3):141–151. https://doi.org/10.1002/sm2.24 CrossRefPubMedPubMedCentral

28.

Mogensen K, Christensen KB, Vrang ML, Hermann GG (2016) Hospitalization for transurethral bladder resection reduces quality of life in Danish patients with non-muscle-invasive bladder tumour. Scand J Urol 50(3):170–174. https://doi.org/10.3109/21681805.2015.1132762 CrossRefPubMed

29.

Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, De la Cerda J, Eagle C, Viner JL, Palmer JL, Lerner SP (2011) A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) 4(10):1580–1589. https://doi.org/10.1158/1940-6207.capr-11-0036 CrossRefPubMedCentral

30.

Schmidt S, Frances A, Lorente Garin JA, Juanpere N, Lloreta Trull J, Bonfill X, Martinez-Zapata MJ, Morales Suarez-Varela M, de la Cruz J, Emparanza JI, Sanchez MJ, Zamora J, Pijoan JI, Alonso J, Ferrer M (2015) Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study. Urol Oncol 33(1):19.e17–19.e15. https://doi.org/10.1016/j.urolonc.2014.09.012 CrossRef

31.

Serretta V, Ruggirello A, Giaimo R, Sommatino F, Billone V, Allegro R, Melloni D (2010) Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study. Urologia 77(4):240–247PubMed

32.

Singer S, Ziegler C, Schwalenberg T, Hinz A, Gotze H, Schulte T (2013) Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer 21(5):1383–1393. https://doi.org/10.1007/s00520-012-1680-8 CrossRefPubMed

33.

Topazio L, Miano R, Maurelli V, Gaziev G, Gacci M, Iacovelli V, et al. (2014) Could hyaluronic acid (HA) reduce Bacillus Calmette-Guerin (BCG) local side effects? Results of a pilot study. BMC Urol. 14:64CrossRefPubMedPubMedCentral

34.

Wei L, Li Q, Liang H, Jianbo L (2014) The quality of life in patients during intravesical treatment and correlation with local symptoms. J Chemother 26(3):165–168. https://doi.org/10.1179/1973947813y.0000000126 CrossRefPubMed

35.

Yokomizo A, Kanimoto Y, Okamura T, Ozono S, Koga H, Iwamura M, Tanaka H, Takahashi S, Tsushima T, Kanayama HO, Akaza H, Shinohara N, Mugiya S, Nomata K, Nakamura T, Naito S (2016) Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Guerin instillation therapy for nonmuscle invasive bladder cancer. J Urol 195(1):41–46. https://doi.org/10.1016/j.juro.2015.08.075 CrossRefPubMed

36.

Yoshimura K, Utsunomiya N, Ichioka K, Matsui Y, Terai A, Arai Y (2005) Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. Urology 65(2):290–294. https://doi.org/10.1016/j.urology.2004.09.050 CrossRefPubMed

37.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe P, Schraub S, Sneeuw K, Sullivan M, Takeda F, for the EORTC Study Group on Quality of Life (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMed

38.

Homma Y, Yoshida M, Yamanishi T, Gotoh M (2008) Core Lower Urinary Tract Symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int J Urol 15(9):816–820. https://doi.org/10.1111/j.1442-2042.2008.02121.x CrossRefPubMed

39.

Guyatt G, Walter S, Norman G (1987) Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 40(2):171–178CrossRefPubMed

40.

Luckett T, King MT (2010) Choosing patient-reported outcome measures for cancer clinical research—practical principles and an algorithm to assist non-specialist researchers. Eur J Cancer 46(18):3149–3157. https://doi.org/10.1016/j.ejca.2010.08.002 CrossRefPubMed

41.

Food and Drug Administration (2009) Patient reported outcome measures: use in medical product development to support labelling claims. US Department of Health & Human Support Food & Drug Administration, MD

42.

Rothman M, Burke L, Erickson P, Kline Leidy N, Patrick DL, Petrie CD (2009) Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO tasck force report. Value Health 12(8):1075–1083. https://doi.org/10.1111/j.1524-4733.2009.00603.x CrossRefPubMed

» This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.